Market Place
Sourcing Support
FDA Confirms Paragraph IV Patent Litigation for Idelalisib.
05 May 2022 //
FDA
Incyte pulls approval filing, following Gilead out of the exitIn
27 Jan 2022 //
FIERCEBIOTECH
Gilead Withdraws Cancer Drug Amidst Uncompleted Follow-Up Trials
24 Jan 2022 //
BIOSPACE
Gilead pulls 2 accelerated approval indications for cancer drug
22 Jan 2022 //
ENDPTS
Gilead withdraws use of Zydelig to treat two types of cancer
15 Jan 2022 //
REUTERS
TG Therapeutics wins FDA nod for potentially safer Zydelig rival
09 Feb 2021 //
FIERCEPHARMA
Micro-cap Mei Pharma lands $100M upfront on beleaguered PI3K pathway
14 Apr 2020 //
ENDPTS
Meet the protein responsible for nearly $100B in cancer drug deals
17 Aug 2019 //
BIOPHARMADIVE
Pharming deal shows there`s still life in struggling cancer drug class
16 Aug 2019 //
BIOPHARMADIVE
ADC Therapeutics Rakes in $303 Million with Addition to its Series E
09 Jul 2019 //
BIOSPACE
AstraZeneca Has Dazzled in Recent Cancer Trials, but Faces Stiff Competition
27 Jun 2019 //
BIOSPACE
AstraZeneca`s Calquence sets Imbruvica in its sights
17 Jun 2019 //
FIERCE PHARMA
AZ`s Calquence chases Imbruvica with phase 3 leukemia win
08 May 2019 //
FIERCE PHARMA
Novartis’ PI3K drug hits goal in phase 3 breast cancer trial
24 Aug 2018 //
FIERCE BIOTECH
Novartis succeeds where Roche failed with PI3K breast cancer drug
23 Aug 2018 //
PHARMAPHORUM
Novartis just boasted of a big PhIII PI3K success
23 Aug 2018 //
ENDPTS
Novartis hands off buparlisib to China`s Adlai Noryte
12 Jul 2018 //
FIERCE BIOTECH
Novartis punts a late-stage PI3K drug to China’s biotechs
12 Jul 2018 //
ENDPTS
Popular keto diet to be tested in humans to check effect of weak PI3K drugs
09 Jul 2018 //
ENDPTS
ASCO: Roche punts taselisib after weak data, severe side effects
04 Jun 2018 //
FIERCE BIOTECH
Roche dumps PhIII taselisib after harsh side effects for breast cancer
03 Jun 2018 //
ENDPTS
MorphoSys seeks $150M IPO to fund late-phase anticancer push
23 Mar 2018 //
FIERCE BIOTECH
Five medicines recommended for approval, including two orphans
23 Feb 2018 //
EMA
Ravindran S to lead PellePharm as CEO; Moderna taps John Mendlein as president
05 Jan 2018 //
END POINTS
Hemo-oncology newbie Bayer gears up for copanlisib launch
13 Sep 2017 //
FIERCE PHARMA
Summary Safety Review - Zydelig (idelalisib) - Assessing the risk of infections
03 Mar 2017 //
HEALTH CANADA
Gilead Hires Alessandro Riva to Lead Oncology R&D Efforts
05 Jan 2017 //
DRUG DEVELOPMENT
MorphoSys begins COSMOS phase 2 trial of MOR208 in combo with idelalisib
14 Dec 2016 //
PHARMABIZ
High prices for some leukemia drugs will make them less cost-effective
21 Nov 2016 //
STAT
3 Potential Acquisition Targets for Gilead Sciences, Inc.
16 Nov 2016 //
THE MOTLEY FOOL
Beaten-down biotechs pin hopes on drug-licensing deal
02 Nov 2016 //
BOSTON GLOBE
AbbVie and Roche`s Leukaemia Drug Venetoclax nears EU Market
18 Oct 2016 //
PM LIVE
Gilead Chief Has $21 Billion in Cash and an Itch to Do a Deal
10 May 2016 //
BLOOMBERG
ZYDELIG (idelalisib) - Increased Risk of Fatal and Serious Infections
03 May 2016 //
HEALTH CANADA
Gilead strategy to develop cancer drugs in doubt after setbacks
18 Mar 2016 //
STAT
Trials in Canada, being stopped due to serious adverse events with drug Zydelig
17 Mar 2016 //
HEALTH CANADA
Gilead`s Zydelig under scrutiny in Europe on safety concerns
14 Mar 2016 //
PHARMA TIMES
Infection worries prompt regulatory reviews of Gilead leukaemia drug
12 Mar 2016 //
REUTERS
EMA puts Gilead`s Zydelig under the lens after deaths crop up in trials
11 Mar 2016 //
FIERCE PHARMA
Opdivo backed for two new uses by CHMP
29 Feb 2016 //
PM LIVE
Gilead’s New CEO, John Milligan, Hints at Probable Mergers and Acquisitions
18 Feb 2016 //
BIOSPACE
Can new PhIII data help Gilead`s Zydelig stage a comeback in CLL?
10 Dec 2015 //
FIERCE PHARMA MARKETING
Venetoclax Is A Powerful New Kind of Cancer Drug Effective In Leukemia
09 Dec 2015 //
FORBES
Gilead leukemia drug trial unblinded early due to success
17 Nov 2015 //
REUTERS
NICE gives nod to Gilead’s Zydelig
24 Sep 2015 //
PM LIVE
NICE asks for more info on Gilead`s Zydelig
19 Jun 2015 //
PHARMA TIMES
Thomson Reuters Names Most Promising Drugs of 2015
23 Mar 2015 //
THOMSON REUTERS
Scotland Oks Seven New Drugs for NHS Use
10 Mar 2015 //
PHARMATIMES
Rare Disease Day 2015
26 Feb 2015 //
EMA
